Dr. Roisin Connolly (IMAGE)

ECOG-ACRIN Cancer Research Group

Dr. Roisin Connolly

Caption

“This was an extremely important study based on the established efficacy benefits of the trastuzumab-pertuzumab combination in HER2-positive breast cancer. We found that select patients with other cancer types with high levels of HER2 amplification benefitted from this approach, which is associated with minimal side effects,” said lead investigator Roisin M.Connolly, MB, BCh, MD, of University College Cork in Ireland, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).

Credit

Cancer Research at University College Cork | UCC Cancer Trials Group

Usage Restrictions

No restrictions.

License

Public Domain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.